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Pulmonary Ground-Glass Opacity (GGO) Lesions–Large
Size and a History of Lung Cancer are Risk Factors
for Growth
Miyako Hiramatsu, MD,*† Takuya Inagaki, MD,* Tomoya Inagaki, MD,* Yoshio Matsui, MD,*
Yukitoshi Satoh, MD, PhD,* Sakae Okumura, MD,* Yuichi Ishikawa, MD, PhD,‡
Etsuo Miyaoka, PhD,§ and Ken Nakagawa, MD*
Objective: Ground-glass opacity (GGO) of the lung is being
frequently detected by thin section computed tomography scan.
However, the long term management of detected GGO is still
unclear. To establish follow-up plans, we performed the clinical
and radiological review to identify the factors that are closely
associated with GGO growth.
Methods: We retrospectively analyzed computed tomography im-
ages of 125 GGOs that were stable for 3 months between 1999 and
2006 at the Cancer Institute Hospital, Tokyo. To identify factors that
affect the roentgenological growth, the time to GGO growth curve
by Kaplan-Meyer method was evaluated in terms of gender, age,
smoking, initial size, existence of a solid part, GGO density, loca-
tion, multiplicity, and lung cancer history by univariate and multi-
variate analyses.
Results: The median observation period was 1048 days (177–3269)
and 26 of 125 GGOs (21%) grew. The estimated growth population
for 5 years was 30%. The growth was more frequently seen in the
elderly (p  0.017), in part-solid GGO (p  0.01) and in GGO of
larger than 10 mm (p 0.01, logrank test). By multivariate analysis,
initial size (p  0.01, Cox’s model) and history of lung cancer (p 
0.017, logistic model) were independent factors that were significantly
associated with GGO growth. Fifty GGOs that were 10 mm or smaller
and without a lung cancer history did not grow within 3.5 years.
Conclusions: After initial management and 3 month follow-up,
larger size (more than 10 mm) and a history of lung cancer are risk
factors for GGO growth, and therefore should be considered when
making a follow-up plan.
Key Words: Lung Adenocarcinoma, Ground-glass, Follow-up,
Thin-section CT.
(J Thorac Oncol. 2008;3: 1245–1250)
Recent studies have demonstrated that screening with low-dose computed tomography (CT) can improve detection
of lung cancer at an early and potentially curable stage.1,2
Since CT screening has become more widely accepted and
with advances in technique, very faint and smaller lesions
called ground-glass opacities (GGOs) are now frequently
encountered. GGO is a roentgenological term for lesions in
the lung on thin section CT (TSCT), defined as a homoge-
neous hazy increase in density in the lung field that does not
obscure the bronchiolovascular structure.3,4 Recently GGOs
were found in 0.2 to 0.5% of screened populations.5 Patho-
logically, localized GGOs existing for months have been
reported to correspond to precancerous lesions or early stage
adenocarcinomas.6–10 These pathologic conditions include
atypical adenomatous hyperplasia (AAH) and bronchioloal-
veolar carcinoma (BAC) which replace alveolar epithelial
cells according to the World Health Organization definition.11
Although GGOs are generally reported to grow slowly, de-
tails of natural history remain limited.12,13
In this study, we therefore examined GGOs and part-solid
GGOs that existed for more than 3 months on chest TSCT in our
hospital. The purpose was to clarify factors that are likely to
affect the growth of a GGO and to gain a better understanding to
facilitate appropriate GGO follow-up planning.
PATIENTS AND METHODS
Patients
Between 1999 and 2006, 184 patients were referred to
the Department of Thoracic Surgical Oncology, the Cancer
Institute Hospital, Tokyo, for further examination of lung
lesions that seemed as a GGO on chest TSCT. Among these,
17 patients (9%) had an immediate diagnostic work-up in-
cluding surgical intervention and 10 patients were lost to
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follow-up. Although the remaining 157 patients were then
followed-up for 3 months by CT scan, it was terminated in 32
patients for the following reasons (number of patients); van-
ished, (6) gross growth, (3) rapid increase in number and
recognition as pulmonary metastasis, (4) advance in other
malignancy, (1) patient’s request, (3) and lost to follow-up.
(11) TSCT was repeated and 125 patients, who showed no
change in the repeat CT images, were finally enrolled in the
study. Their clinicopathologic background and CT findings
are shown in Table 1. Although 45 patients (36%) had
multiple GGOs (range of number, 2–20), we only considered
the largest lesions. Follow-up consisted of periodic TSCT at
a 6-month intervals. The mean observation period was 1048
days (ranged, 177–3269), and follow-up CT scans were
performed an average of 6 times in each case. In 59 cases,
GGOs were detected at a health check-up or were found
incidentally, and the others were detected during follow-up of
prior malignancy (51 patients with lung adenocarcinoma
(stage I, 48; stage II, 1; stage III, 2), 9 with breast cancer, 2
with gynecologic cancer, 2 with urologic cancer, and 2 with
sarcomas). Nine patients with a history of lung cancer also
had other cancers in other organs. The interval between the
prior malignancy treatment and detection of the current GGO
varied from 0 to 168 (mean 36) months among these 66
patients.
This retrospective study was approved by the institu-
tional review board of the Cancer Institute Hospital of the
Japanese Foundation for Cancer Research.
Radiologic Definition of GGOs and Their
“Growth” on TSCT
CT scan was performed with a GE Yokogawa Medical
System, Light Speed QXi or High Speed DXi (Hino, Tokyo).
For screening of the whole lung field, the scanning parame-
ters were as follows: 120 kV, 230 mA, beam width of 7.5
mm, rotation speed of 1 revolution/s, table speed of 15 mm/s
(pitch 2:1), and a reconstruction interval of 7.5 mm. When the
presence of GGO was suspected, targeted axial scanning was
repeated only for the suspected area based on the previous
scanning. The scanning parameters were 120 kV, 280 mA (or
180 mA), clustered axial scanning of 1.25 mm or 2.0 mm
slice and the largest diameter of the lesion was evaluated at
WL-585HU and WW1800HU.14 All scans were obtained in
full inspiration without any contrast material and viewed in
cine format on a computer workstation. All radiologic images
were evaluated by 2 of the specialists who had 5 and 17 years
of experience (MH, YS), respectively and a final consensus
was obtained by plenary reading. The size of each lesion was
recorded by evaluating the largest diameter using a caliper
tool in the software. In this study, we discriminate “part-solid
GGO” from “GGO.” The definition of them was based on
that of Henschke et al.,15 in which the subcategories “non-
solid” and “part-solid” were recognized according to the
absence/presence of solid parts in the GGO lesion. We prefer
the term “GGO” to “nonsolid nodule” because a finding of
GGO on TSCT corresponds specifically to a pathologic
alveolar condition with noninvasive tumor-spreading, while
“nonsolid nodule” does not. The remainder (24%) had a solid
part, the diameter of which as a proportion of the diameter of
the whole lesion was (solid part/ GGO) from 0.13 to 0.42
(2/16 mm–2.5/6 mm) and we used the term “part-solid GGO”
for them in this study. All GGOs with extra findings (6 GGOs
with cystic components and 12 GGOs with heterogeneous
ground-glass density) were included as “GGO.” The “CT
density” was defined as the mean density (HU) measured at
three spots within the GGO part of each lesion with the
software tool. “Growth” of a GGO was concluded when any
of the following were recognized: gross increase in the
greatest dimension by at least 2 mm from the initial TSCT
(Figure 1), gross increase in the size of the solid part by at
least 2 mm, or a new solid part of any size (Figure 2).
Statistical Analysis
The follow-up time was defined from the date of the
initial TSCT to the latest TSCT. To clarify the factors that
may affect GGO growth, univariate and multivariate analyses
were performed with regard to the growth incidence (num-
bers of GGO with concluded growth/numbers at risk). In this
retrospective investigation, multivariate analyses were ap-
TABLE 1. Patient Background and CT Findings
Total With Growth
n  125 n  26 (%)
Patient background
Gender
Men 51 13 (25)
Women 74 13 (18)
Age (36–88, mean 62)
60 44 5 (11)
60 81 21 (26)
Smoking habit
Never 58 10 (17)
Ever 41 10 (24)
Unknown 26 6 (23)
History of lung cancer
Without 74 11 (15)
With 51 15 (29)
CT findings
Initial size (3–17 mm, mean 8.3)
10 87 8 (9)
10 38 18 (47)
Existence of solid part
Without (GGO) 95 14 (15)
With (part-solid GGO) 30 12 (40)
CT density (810 to 10 HU)a
500 67 10 (15)
500 58 16 (28)
Locationb
Above 79 19 (24)
Below 46 7 (15)
Multiplicity
Solitary 80 17 (21)
Multiple 45 9 (20)
a The mean CT density (HU) of 3 spots within the GGO.
b With reference to the major fissure of the lung.
GGO, ground-glass opacity; CT, computed tomography.
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plied for two separate studies: one to evaluate the time to
GGO growth and the other to evaluate GGO growth inci-
dence. For the first, the time to GGO growth curves were
estimated by the Kaplan-Meier method, and the difference of
the time to GGO growth curve between each group was tested
by the log-rank test. Independent variables that influenced the
time to GGO growth were analyzed by Cox’s proportional
hazard model. For the analysis, the original continuous vari-
ables, such as age, CT density (HU), and initial size, were
dichotomized at clinically appropriate cutoff values (60
years, 500 HU and 10 mm, respectively). In the second
study, a logistic-regression analysis was performed to clarify
variables that affected GGO growth incidence. Finally, vari-
ables were selected by multivariate matched sampling meth-
ods in both studies.
RESULTS
Characteristics of GGOs with Growth
The clinical and radiologic characteristics of all cases
were presented in Table 1. Among 125 patients with GGOs
who underwent repeated TSCT for 3 months or more, 26
patients (21%) had overt GGO growth which met our defi-
nitions. With 13 GGOs (10%), enlargement of the greatest
dimension was documented. These lesions consisted of 8
GGOs of 5 to 13 mm and 5 part-solid GGOs of 8 to 16 mm,
and 2 of each had a history of lung cancer. An increase in
both the greatest dimension and the size of the solid part was
evident in 7 part-solid GGOs (6%) of 11 to 17 mm. Six GGOs
measuring 8 to 16 mm became part-solid GGOs (5%).
The histopathological features were studied in 9 GGOs
with growth. Specimens were obtained by surgical explora-
tion in 7 (5 with lobectomy and 2 with segmentectomy), and
by fine needle aspiration and by transbronchial lung biopsy in
one each. The histologic diagnosis was made according to the
World Health Organization classification11: adenocarcinoma
with mixed subtype was seen in 6, nonmucinous BAC in 2, and
organizing pneumonia in one. Of these 9 GGOs that underwent
evaluation, 6 were detected at a health check-up and the rest
were detected more than 2 years after an operation for stage I
lung cancer. In contrast, 9 of the remaining 17 cases with
growing GGOs had advanced tumors. Further evaluation was
applied mainly depending on the background and the patient’s
request, particularly in the earlier period because the natural
history of GGO had not yet been well described. No metastasis
or tumor-related deaths were observed clinically.
Time to GGO Growth Curves and Univariate
Analysis for Factors that Affect the Time to
GGO Growth
The time to GGO growth curve for 125 GGOs is shown
in Figure 3. Growth incidence at 3 and 5 years were estimated
FIGURE 1. A case showing GGO increase in
size. (A) GGO in the left upper lobe, measuring
7 mm in diameter at detection. (B) Growth by
3 mm was confirmed after 10 months.
FIGURE 2. A case with GGO increase in size
and formation of a solid part. (A) 9 mm and 7
mm GGOs detected in the left upper lobe. (B)
Growth in size (to 17 and 12 mm, respectively)
and became part-solid GGO after 7 months.
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to be 18% and 30%, respectively, with no plateau. Statisti-
cally significant influence on time to growth was evident for
age (p  0.017), existence of solid part (p  0.01) and initial
size (p  0.01). With regard to the initial size of GGO, we
determined an appropriate cutoff size by using the time to
GGO growth curve and found that 2 curves were maximally
distinguished with an initial size of 10 mm. However, no
differences in the time to GGO growth were observed ac-
cording to such clinical factors as gender, smoking habit,
history of lung cancer, or radiologic findings like size, exis-
tence of solid part, CT density, location, or multiplicity
(Table 2). The time to GGO growth curves with reference to
initial sizes (10 mm or smaller and larger than 10 mm) are
shown in Figure 4 and the growth incidence of each group at
5 years were estimated to be 14% and 66%, respectively, the
difference being statistically significant (p  0.01).
Multivariate Analyses for Factors that Affect
GGO Growth
The results of the multivariate analysis by Cox’s pro-
portional hazard model are shown in Table 3. Only initial size
was significantly associated with the time to GGO growth
(p  0.01). In contrast, both the initial size (p  0.018) and
FIGURE 3. The time to GGO growth curve for the 125
GGOs. The growth incidence at 5 years was estimated to be
30% in this study.
FIGURE 4. The time to GGO growth curves according to
initial size of GGO. The growth incidence for 10 mm or
smaller (n  87) and larger (n  38) at 5 years were 14%
and 66%, respectively. The difference between the curves
was statistically significant (p  0.01).
TABLE 2. Univariate Analysis for Factors Affecting the Time
to GGO Growth
Variables
Estimated
Probability
p3 yr 5 yr
Gender 0.15
Men 0.26 0.39
Women 0.13 0.25
Age 0.017
60 0.09 0.13
60 0.23 0.41
Smoking habit 0.16
Never 0.09 0.23
Ever 0.29 0.41
History of lung cancer 0.22
With 0.19 0.22
Without 0.16 0.38
Initial size 0.01
10 0.04 0.14
10 0.49 0.66
Existence of solid part 0.01
Without (GGO) 0.12 0.18
With (part-solid GGO) 0.43 0.80
CT density (HU) 0.17
500 0.16 0.20
500 0.20 0.40
Locationa 0.78
Above 0.19 0.31
Below 0.13 0.28
Multiplicity 0.60
Solitary 0.22 0.35
Multiple 0.10 0.23
a With reference to the major fissure of the lung.
GGO, ground-glass opacity; CT, computed tomography.
TABLE 3. Multivariate Analysis for Factors Affecting the
Time to GGO Growth by Cox Proportional Hazard Model
SD HR 95% CI p
Gender 0.55 0.71 0.24–2.11 0.54
Age 0.028 1.00 0.95–1.06 0.79
History of lung cancer 0.61 2.15 0.65–7.15 0.21
Smoking habit 0.60 1.54 0.47–5.12 0.68
Initial size 0.085 1.28 1.08–1.51 0.01
Existence of solid part 0.76 1.66 0.37–7.37 0.51
CT density (HU) 0.002 1.00 0.99–1.00 0.89
Location 0.56 0.86 0.29–2.57 0.79
Multiplicity 0.55 0.63 0.21–1.85 0.40
Final model
Initial size 0.06 1.36 1.21–1.53 0.01
GGO, ground-glass opacity; SD, standard deviation; HR, hazard ratio; CI, confident
interval.
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history of lung cancer (p  0.033) were independent factors
that were significantly associated with GGO growth on mul-
tivariate analysis of logistic regression (Table 4). The factor
“history of lung cancer” seemed to influence the growth
incidence after the third year of follow-up and this might be
the reason why this parameter became significant only when
using the logistic regression model. The time to GGO growth
curves according to the initial size and history of lung cancer
were shown in Figure 5. The growth population of 50 GGOs
that were 10 mm or smaller and without a history of lung
cancer stayed 0% until 42 months. However, the growth
population of other GGOs started to rise within the first year.
DISCUSSION
Localized GGOs found on high-resolution chest CT
scans have been reported to correspond histologically to
preinvasive or early stage forms of adenocarcinoma.6–11 Al-
though the natural history of GGOs is speculated to corre-
spond to progression from AAH to invasive adenocarcinoma,
sequential changes are not well detailed. Clinically, localized
GGOs are considered to exhibit slow growth.12 Hasegawa et
al. showed that the tumor doubling times of GGOs and
solid-type lesions were 813  375 and 149  125 days,
respectively.13 Since biopsy or excision of these lesions in the
lung is relatively difficult, these slow growing GGOs are
currently considered for follow-up instead of definite diag-
nosis or treatment.16,17 However, an appropriate follow-up
period and a consensus intervention strategy have yet to be
determined.
Recently, a close correlation between the size of re-
sected GGOs and histology was reported. Nakata et al.
analyzed GGOs less than 2 cm in diameter and found that the
average sizes for AAH, BAC, and adenocarcinoma were 6.8
mm, 10.0, and 12.5 mm, respectively; the difference being
statistically significant.7 According to Takashima et al. lesion
size, percentage of GGO area within a lesion, lobulation,
coarse spiculation, air bronchogram, cavity, a pleural tag, and
a solid portion are related to histopathological diagnosis as
AAH, BAC, or adenocarcinoma.18 Furthermore, the growth
fraction of these tumor cells is known to increase according to
sequential progression from AAH to BAC then adenocarci-
noma.19 These observations suggested that larger GGOs are
more likely to have an invasive character, and therefore a
high growth incidence can reasonably be expected for larger
GGOs. In the present study, 26 of 125 GGOs (21%) showed
obvious growth during the follow-up period, and the initial
size of GGO was identified as an independent factor that
affected GGO growth incidence and the time to GGO growth
on multivariate analyses. In the International Early Lung
Cancer Action Project protocol, observation and follow-up
CT scan within a few months is recommended for any GGO
8 to 15 mm in diameter.16 In the present study, the difference
in growth population curves for GGOs 10 mm or smaller and
GGOs larger than 10 mm was statistically significant. There-
fore the interval of follow-up TSCT for each case should be
set differently according to the initial size.
Moreover, our multivariate analysis demonstrated that
a past history of lung cancer was also an independent factor
affecting the growth of GGO. Kodama et al. reported similar
observations; 19 GGOs were followed up, and growth was
seen in 6 of 7 GGOs with a history of lung cancer but in only
4 of 12 GGOs without such a history.20 Although the reason
for the higher growth incidence in patients with a history of
lung cancer is unclear, one possibility is that these newly
developing GGOs are intrapulmonary metastases or recur-
rences. However, none of our 51 patients with a past history
of lung cancer developed extrathoracic metastasis or bilateral
multiple metastasis during the follow-up period. Therefore,
the significant percentage in the present series can not be
explained on this basis. Also, in CT images, recurrent in-
trapulmonary metastases are not likely to present with a GGO
appearance.5,21 Another possibility is that these GGOs are
metachronous second primary lesions with a more aggressive
nature and a faster speed of growth. In previous reports, the
prevalence of second primary lung cancers was reported to be
0.8 to 10.0%, and the 5-year survival rate after the develop-
ment of metachronous lesion varied from 18 to 39%.22–26
FIGURE 5. The time to GGO growth curve was divided ac-
cording to the initial size and a history of lung cancer. Fifty
GGOs that were 10 mm or less in diameter and without a
previous history of lung cancer did not grow within the fol-
low-up period of 42 months.
TABLE 4. Multivariate Analysis for Factors Affecting the
Time to GGO Growth by Logistic Regression
SD OR 95% CI p
Gender 0.78 0.47 0.10–2.16 0.33
Age 0.035 0.99 0.93–1.07 0.95
History of lung cancer 0.74 4.80 1.13–20.33 0.033
Smoking habit 0.76 0.91 0.21–4.03 0.91
Initial size 0.11 1.29 1.05–1.60 0.018
Existence of solid part 0.80 1.84 0.39–8.75 0.44
CT density (HU) 0.002 1.00 0.99–1.005 0.70
Location 0.67 0.62 0.17–2.29 0.47
Multiplicity 0.69 0.53 0.14–2.05 0.36
Final model
Initial size 0.080 1.42 1.21–1.66 0.01
History of lung cancer 0.53 3.51 1.25–9.88 0.017
GGO, ground-glass opacity; SD, standard deviation; OR, odds ratio; CI, confident
interval.
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However, these reports considered only solid tumors of
different histologies and of larger size than recent CT de-
tected tumors, so much better survival is expected for GGOs
even with a prior history of lung cancer. Without genetic
confirmation, it is difficult to distinguish between metastasis
or recurrence and second primary tumor, even with a com-
parison of histology.27,28 In the present study, however, it was
strongly suggested that the GGOs need to be carefully fol-
lowed-up in patients with a history of lung cancer.
The timing of terminating the follow-up is another
important issue in the management of GGO. In the present
study, 50 GGOs that were 10 mm or less in diameter and
without a previous history of lung cancer did not grow within
the follow-up period of 42 months. Although the number of
patients studied here was not large, these data suggested that
the interval between the initial CT and the second CT for such
GGOs could be extended to at least 3 years. Further accu-
mulation of data is crucial to establish an appropriate fol-
low-up strategy for patients with GGO lesions with varied
backgrounds.
In conclusion, independent factors that significantly
affect the growth of GGO were initial size, in particular larger
than 10 mm, and a history of lung cancer in our series.
Therefore, in the follow-up/work-up strategy for GGOs, these
two factors should be taken into consideration so as not to
overlook aggressive tumors. It is also important to note that
these recommendations should be applied only after initial
management and a 3-month follow-up have been performed.
The possibility of putting-off the follow-up CT for 3 years for a
GGO of 10 mm or smaller in a patient without any history of
lung cancer should also be explored. In contrast, follow-up CT
within a year should be recommended for larger GGOs or GGOs
with a history of lung cancer.
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